GLP-1 drugs don’t work for everyone. But personalized obesity care in the future might
As doctors learn why GLP-1s don’t work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the way cancer is treated now. (Image credit: Tatsiana Volkava)
Roche sees GLP1/GIP drug from Carmot produce 22.5% weight loss, readies phase 3 trial
Roche’s dual GLP-1/GIP receptor agonist has been tied to 22.5% weight loss at 48 weeks, validating the company’s decision to move the asset into phase 3 studies in the coming weeks.
Havas’ GLP-1 Consultancy takes center stage at 1 Billion Followers Summit in Dubai
As GLP-1 adoption accelerates across the Middle East, Havas brings a unique specialized strategic cultural lens to the rapidly evolving metabolic economy
Baseline Therapeutics Launches to Advance GLP-1RA Phase 3 Program in Alcohol Use Disorder
SAN FRANCISCO–(BUSINESS WIRE)– #SUD–Baseline Therapeutics, Inc. (“Baseline”), a clinical-stage biotechnology company developing addiction therapeutics, today announced the launch of the company to advance a new generation of pharmacotherapies for substance use disorders. Baseline’s lead program, BT-001, is a best-in-class, once-weekly GLP-1 receptor agonist (GLP-1RA) candidate being developed for alcohol use disorder (AUD), with additional substance […]
GLP-1 Meds Are Bringing Back Our Eating Disorders
Where Will Eli Lilly Be in 10 Years?
If you follow the news at all, you know that GLP-1 weight loss drugs are having a massive impact on society. The leader in the GLP-1 space today is Eli Lilly (NYSE: LLY). That helps explain why Wall Street is so excited about the company’s stock, pushing its price-to-earnings (P/E) ratio to a whopping 53 […]
STAT+: New startup to develop a GLP-1 drug for addiction
Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. A new startup focused on GLP-1 drugs launched today, but unlike the dozens of other GLP-1 companies, this one isn’t studying weight loss. The need-to-know this morning Roche plans to launch Phase […]
Where Will Eli Lilly Be in 10 Years?
Key Points The pharmaceutical industry has a well-structured cycle. Eli Lilly is currently benefiting from the early stages of the cycle. In 10 years, if not sooner, investors will begin to worry about Eli Lilly’s future beyond GLP-1 drugs. 10 stocks we like better than Eli Lilly › If you follow the news at all, […]
Donald Trump couldn’t remember the word ‘Alzheimer’s,’ his father’s condition
Instead of focusing on Donald Trump’s profound cognitive decline and his visibly terrible health during the 2024 election, the media has only *really* started talking about Trump’s health in the past year. They have to be dragged kicking and screaming into the discussion too, because they really couldn’t care less about their despicable double-standards and […]
One-shot weight loss: Can gene therapy actually replace the GLP-1 revolution?
Gene therapy for weight loss is being explored as a potential game-changer, with therapy aiming to program the body to produce its own GLP-1 hormone naturally.